KFKevin Franks

Kevin Franks

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kevin Franks has a total of 152 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Assessment of patient-reported symptom and psychological distress after neoadjuvant chemo-immunotherapy and lung resection for non-small cell lung cancer

    by Cecilia Pompili, Javeria Tariq, Pooja Bhatnagar, Nick Brown, Nilanjan Chaudhuri, Katy Clarke, Sun Fei, Kevin Franks, Joshil Lodhia, Richard Milton, et al.

    Objectives: Neoadjuvant chemo-immunotherapy is associated with oncologic benefits in patients undergoing resection for locally advanced non-small cell lung cancer (NSCLC). We assessed patient-reported physical and psychological symptoms following neoadjuvant chemo-immunotherapy and surgery compared to stage-equivalent patients who were operated during the same period without neodjuvant treatment. Methods: All consecutive patients submitted to lung resection for clinical stage II and III NSCLC between March 2023 and December 2024 and alive at the time of the interview were approached for the study. Their patient-reported symptoms were assessed using the Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ) and their psychological distress was assessed using the Hospital Anxiety and Depression Scale (HADS). Results: Of the 138 patients initially screened, 82 completed the survey. Median time from surgery to the interview was 13.9 months. There was no difference in total NSCLC-SAQ score between patients undergoing upfront surgery (S) and surgery after neoadjuvant chemo-immunotherapy (CT-IO) (P = .64). Chemo-immunotherapy was not independently associated with total NSCLC-SAQ score after multivariable regression analysis. The average anxiety and depression scores were also similar between the 2 groups. Finally, a similar proportion of patients in the 2 groups reported to have symptoms similar or better than before starting treatment. Conclusions: Our findings show in a real clinical practice setting that neoadjuvant chemo-immunotherapy is not negatively associated with patient-reported physical or psychological symptoms in the medium to long-term follow-up compared to surgery alone. These results can be used as information tool during patients’ counselling.


  • Open Access

    Clinical characteristics and outcomes in participants with screen-detected clinical stage I lung cancer in the Yorkshire lung screening trial: A comparison of surgery versus stereotactic ablative radiotherapy

    by Hannah R. Bailey, Hui Zhen Tam, Daniel Vulkan, Alessandro Brunelli, Philip A.J. Crosbie, Kevin N. Franks, Rhian Gabe, Martyn P.T. Kennedy, Matthew E.J. Callister

  • Delivering equitable access to prehabilitation services to optimise outcomes for patients with lung cancer – Best practice recommendations from a UK roundtable event

    by William Ricketts, Catherine Sandsund, Zoe Merchant, Kevin Franks, Cecilia Pompili, Andriana Petrova, Asanga Fernando, Pamela Dalrymple, Babu Naidu, Lucy Gossage, et al.


  • Open Access

    CODAK: Real-World Clinical Outcomes of Patients With Unresectable, Stage III Non–Small Cell Lung Cancer Treated With Durvalumab After Chemoradiotherapy in the United Kingdom

    by K. Franks, D. Smith, P. Shaw, G.L. Banna, M. Cominos, T. Talbot, B.T. Blak, L. Lindqvist-Brown, M. Ahmed


  • Optimal management of radiation pneumonitis: Findings of an international Delphi consensus study

    by Indu S. Voruganti Maddali, Cicely Cunningham, Lorraine McLeod, Houda Bahig, Nazia Chaudhuri, Kevin L. M. Chua, Matthew Evison, Corinne Faivre-Finn, Kevin Franks, Susan Harden, et al.


  • Open Access

    Participation in community-based lung cancer screening: the Yorkshire Lung Screening Trial

    by Philip A. J. Crosbie, Rhian Gabe, Irene Simmonds, Neil Hancock, Panos Alexandris, Martyn Kennedy, Suzanne Rogerson, David Baldwin, Richard Booton, Claire Bradley, et al.

    Background: Screening with low-dose computed tomography (LDCT) reduces lung cancer mortality; however, the most effective strategy for optimising participation is unknown. Here we present data from the Yorkshire Lung Screening Trial, including response to invitation, screening eligibility and uptake of community-based LDCT screening.Methods: Individuals aged 55–80 years, identified from primary care records as having ever smoked, were randomised prior to consent to invitation to telephone lung cancer risk assessment or usual care. The invitation strategy included general practitioner endorsement, pre-invitation and two reminder invitations. After telephone triage, those at higher risk were invited to a Lung Health Check (LHC) with immediate access to a mobile CT scanner.Results: Of 44 943 individuals invited, 50.8% (n=22 815) responded and underwent telephone-based risk assessment (16.7% and 7.3% following first and second reminders, respectively). A lower response rate was associated with current smoking status (adjusted OR 0.44, 95% CI 0.42–0.46) and socioeconomic deprivation (adjusted OR 0.58, 95% CI 0.54–0.62 for the mostversusthe least deprived quintile). Of those responding, 34.4% (n=7853) were potentially eligible for screening and offered a LHC, of whom 86.8% (n=6819) attended. Lower uptake was associated with current smoking status (adjusted OR 0.73, 95% CI 0.62–0.87) and socioeconomic deprivation (adjusted OR 0.78, 95% CI 0.62–0.98). In total, 6650 individuals had a baseline LDCT scan, representing 99.7% of eligible LHC attendees.Conclusions: Telephone risk assessment followed by a community-based LHC is an effective strategy for lung cancer screening implementation. However, lower participation associated with current smoking status and socioeconomic deprivation underlines the importance of research to ensure equitable access to screening.


  • Open Access

    Chemotherapy use and outcomes in patients with stage III or IV small-cell lung cancer in relation to age: An analysis of the English Systemic Anti-Cancer Treatment (SACT) dataset

    by Sophie Pilleron, Eva Ja Morris, David Dodwell, Kevin Franks

    Introduction: Survival from small cell lung cancer (SCLC) is poor and there has been little progress in treatment. There is little evidence on outcomes in patients aged 75+. We described patterns of chemotherapy use and outcomes using the national Systemic Anti-Cancer Treatment dataset in patients with stage III or IV SCLC in relation to age. Method: We included 7,966 SCLC (67.6% stage IV) diagnosed between 2014-17 in England, treated with chemotherapy and followed up through 2017. Patterns of chemotherapy use, 30- and 90-mortality rates, 6-,12-month and median overall survival (OS) from the start of the first chemotherapy cycle were compared between those below and above the age of 75. OS was estimated using Kaplan Meier estimator and modeled using a flexible hazard regression model. Results: Older patients were 6-7 times less likely to receive curative treatment than younger patients regardless of stage. There were more frequent adjustments of treatment and dose reduction (stage III) in older than younger patients but no age-related differences in reduction of doses (stage IV), treatment delayed or stopped earlier than planned. Although 30-day mortality rates were similar across age groups in stage III SCLC (∼4%), older patients had higher early mortality and poorer OS than younger peers. In both stages, 6 and 12-month OS by age decreased around the age of 70-75 and were worse in patients with performance status scores ≥2. Conclusion: This study offers a snapshot of chemotherapy use and outcomes in advanced SCLC, notably in older patients, in the pre-immunotherapy era.

  • Electronic self-reporting of adverse events for patients undergoing cancer treatment: the eRAPID research programme including two RCTs

    by Galina Velikova, Kate Absolom, Jenny Hewison, Patricia Holch, Lorraine Warrington, Kerry Avery, Hollie Richards, Jane Blazeby, Bryony Dawkins, Claire Hulme, et al.

    Background: Cancer is treated using multiple modalities (e.g. surgery, radiotherapy and systemic therapies) and is frequently associated with adverse events that affect treatment delivery and quality of life. Regular adverse event reporting could improve care and safety through timely detection and management. Information technology provides a feasible monitoring model, but applied research is needed. This research programme developed and evaluated an electronic system, called eRAPID, for cancer patients to remotely self-report adverse events. Objectives: The objectives were to address the following research questions: is it feasible to collect adverse event data from patients’ homes and in clinics during cancer treatment? Can eRAPID be implemented in different hospitals and treatment settings? Will oncology health-care professionals review eRAPID reports for decision-making? When added to usual care, will the eRAPID intervention (i.e. self-reporting with tailored advice) lead to clinical benefits (e.g. better adverse event control, improved patient safety and experiences)? Will eRAPID be cost-effective? Design: Five mixed-methods work packages were conducted, incorporating co-design with patients and health-care professionals: work package 1 – development and implementation of the electronic platform across hospital centres; work package 2 – development of patient-reported adverse event items and advice (systematic and scoping reviews, patient interviews, Delphi exercise); work package 3 – mapping health-care professionals and care pathways; work package 4 – feasibility pilot studies to assess patient and clinician acceptability; and work package 5 – a single-centre randomised controlled trial of systemic treatment with a full health economic assessment. Setting: The setting was three UK cancer centres (in Leeds, Manchester and Bristol). Participants: The intervention was developed and evaluated with patients and clinicians. The systemic randomised controlled trial included 508 participants who were starting treatment for breast, colorectal or gynaecological cancer and 55 health-care professionals. The radiotherapy feasibility pilot recruited 167 patients undergoing treatment for pelvic cancers. The surgical feasibility pilot included 40 gastrointestinal cancer patients. Intervention: eRAPID is an online system that allows patients to complete adverse event/symptom reports from home or hospital. The system provides immediate severity-graded advice based on clinical algorithms to guide self-management or hospital contact. Adverse event data are transferred to electronic patient records for review by clinical teams. Patients complete an online symptom report every week and whenever they experience symptoms. Main outcome measures: In systemic treatment, the primary outcome was Functional Assessment of Cancer Therapy – General, Physical Well-Being score assessed at 6, 12 and 18 weeks (primary end point). Secondary outcomes included cost-effectiveness assessed through the comparison of health-care costs and quality-adjusted life-years. Patient self-efficacy was measured (using the Self-Efficacy for Managing Chronic Diseases 6-item Scale). The radiotherapy pilot studied feasibility (recruitment and attrition rates) and selection of outcome measures. The surgical pilot examined symptom report completeness, system actions, barriers to using eRAPID and technical performance. Results: eRAPID was successfully developed and introduced across the treatments and centres. The systemic randomised controlled trial found no statistically significant effect of eRAPID on the primary end point at 18 weeks. There was a significant effect at 6 weeks (adjusted difference least square means 1.08, 95% confidence interval 0.12 to 2.05; p = 0.028) and 12 weeks (adjusted difference least square means 1.01, 95% confidence interval 0.05 to 1.98; p = 0.0395). No between-arm differences were found for admissions or calls/visits to acute oncology or chemotherapy delivery. Health economic analyses over 18 weeks indicated no statistically significant difference between the cost of the eRAPID information technology system and the cost of usual care (£12.28, 95% confidence interval –£1240.91 to £1167.69; p > 0.05). Mean differences were small, with eRAPID having a 55% probability of being cost-effective at the National Institute for Health and Care Excellence-recommended cost-effectiveness threshold of £20,000 per quality-adjusted life-year gained. Patient self-efficacy was greater in the intervention arm (0.48, 95% confidence interval 0.13 to 0.83; p = 0.0073). Qualitative interviews indicated that many participants found eRAPID useful for support and guidance. Patient adherence to adverse-event symptom reporting was good (median compliance 72.2%). In the radiotherapy pilot, high levels of consent (73.2%) and low attrition rates (10%) were observed. Patient quality-of-life outcomes indicated a potential intervention benefit in chemoradiotherapy arms. In the surgical pilot, 40 out of 91 approached patients (44%) consented. Symptom report completion rates were high. Across the studies, clinician intervention engagement was varied. Both patient and staff feedback on the value of eRAPID was positive. Limitations: The randomised controlled trial methodology led to small numbers of patients simultaneously using the intervention, thus reducing overall clinician exposure to and engagement with eRAPID. Furthermore, staff saw patients across both arms, introducing a contamination bias and potentially reducing the intervention effect. The health economic results were limited by numbers of missing data (e.g. for use of resources and EuroQol-5 Dimensions). Conclusions: This research provides evidence that online symptom monitoring with inbuilt patient advice is acceptable to patients and clinical teams. Evidence of patient benefit was found, particularly during the early phases of treatment and in relation to self-efficacy. The findings will help improve the intervention and guide future trial designs. Future work: Definitive trials in radiotherapy and surgical settings are suggested. Future research during systemic treatments could study self-report online interventions to replace elements of traditional follow-up care in the curative setting. Further research during modern targeted treatments (e.g. immunotherapy and small-molecule oral therapy) and in metastatic disease is recommended. Trial registration: The systemic randomised controlled trial is registered as ISRCTN88520246. The radiotherapy trial is registered as ClinicalTrials.gov NCT02747264. Funding: This project was funded by the National Institute for Health Research (NIHR) Programme Grants for Applied Research programme and will be published in full in Programme Grants for Applied Research; Vol. 10, No. 1. See the NIHR Journals Library website for further project information.


  • Open Access

    Causes of Death in People With Cardiovascular Disease: A UK Biobank Cohort Study

    by Michael Drozd, Mar Pujades‐Rodriguez, Fei Sun, Kevin N. Franks, Patrick J. Lillie, Klaus K. Witte, Mark T. Kearney, Richard M. Cubbon

    Background: Therapeutic advances have reduced cardiovascular death rates in people with cardiovascular diseases (CVD). We aimed to define the rates of cardiovascular and noncardiovascular death in people with specified CVDs or accruing cardiovascular multimorbidity. Methods and Results: We studied 493 280 UK residents enrolled in the UK Biobank cohort study. The proportion of deaths attributed to cardiovascular, cancer, infection, or other causes were calculated in groups defined by 9 distinct self‐reported CVDs at baseline, or by the number of these CVDs at baseline. Poisson regression analyses were then used to define adjusted incidence rate ratios for these causes of death, accounting for sociodemographic factors and comorbidity. Of 27 729 deaths, 20.4% were primarily attributed to CVD, 53.6% to cancer, 5.0% to infection, and 21.0% to other causes. As cardiovascular multimorbidity increased, the proportion of cardiovascular and infection‐related deaths was greater, contrasting with cancer and other deaths. Compared with people without CVD, those with 3 or more CVDs experienced adjusted incidence rate ratios of 7.0 (6.2–7.8) for cardiovascular death, 4.4 (3.4–5.6) for infection death, 1.5 (1.4–1.7) for cancer death, and 2.0 (1.7–2.4) for other causes of death. There was substantial heterogeneity in causes of death, both in terms of crude proportions and adjusted incidence rate ratios, among the 9 studied baseline CVDs. Conclusions: Noncardiovascular death is common in people with CVD, although its contribution varies widely between people with different CVDs. Holistic and personalized care are likely to be important tools for continuing to improve outcomes in people with CVD.